Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from France
- 1 September 2003
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 22 (9) , 561-565
- https://doi.org/10.1007/s10096-003-0990-7
Abstract
The aim of the study presented here was to evaluate the in vitro activity of faropenem, a new member of the penem class intended for oral administration, compared with 11 other antimicrobial agents against a large number of Streptococcus pneumoniae strains isolated from adults and children with bloodstream infections in France. The minimum inhibitory concentration of faropenem against 90% of the pediatric strains tested was generally one to two dilutions lower than the most potent beta-lactam agents (i.e., 0.5 µg/ml for faropenem vs. 1 for amoxicillin, 1 for cefotaxime and 0.5 µg/ml for ceftriaxone). Against the adult strains, only moxifloxacin had a MIC90 value similar to faropenem (i.e., 0.25 µg/ml for both agents). Faropenem seems to be a promising antimicrobial agent for the treatment of adult and pediatric Streptococcus pneumoniae infections.Keywords
This publication has 18 references indexed in Scilit:
- Global antibiotic resistance in Streptococcus pneumoniaeJournal of Antimicrobial Chemotherapy, 2002
- In vitro activity of faropenem against respiratory pathogens.Journal of Antimicrobial Chemotherapy, 2002
- In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae.Journal of Antimicrobial Chemotherapy, 2001
- Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparisonJournal of Antimicrobial Chemotherapy, 2001
- Fatal Pneumococcal Pneumonia Attributed to Macrolide Resistanceand Azithromycin MonotherapyChest, 2000
- Impact of Penicillin Susceptibility on Medical Outcomes for Adult Patients with Bacteremic Pneumococcal PneumoniaClinical Infectious Diseases, 2000
- The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infectionsJournal of Antimicrobial Chemotherapy, 2000
- Management of Infections Due to Antibiotic-Resistant Streptococcus pneumoniaeClinical Microbiology Reviews, 1998
- The in-vitro activity of faropenem, a novel oral penemJournal of Antimicrobial Chemotherapy, 1997
- In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinirAntimicrobial Agents and Chemotherapy, 1994